Update on TB Vaccines Mark Hatherill South African TB Vaccine
Initiative (SATVI) University of Cape Town 1
Slide 2
Robert Kochs Therapeutic TB vaccine 1890: Purified Tuberculin
Protein 1891: First negative reports of clinical trials Total 1769
patients More patients died during therapy than were cured Fewer
that 20% of all patients improved substantially 50% showed no
improvement at all
Slide 3
3 1921: Bacille Calmette-Guerin (BCG) Albert Calmette
(physician) and Camille Guerin (vet), Pasteur Institute, Lille,
France Attenuated cow TB strain (M. bovis)
Slide 4
Does BCG work? Trials and observational studies 0 - 81%
protection Vaccine efficacy varies by latitude, age group, type of
disease, among other things.. 4
Slide 5
5 Does BCG work in children? Clinical trials in infants: 74%
protection against TB disease (all forms) But the last infant trial
was published half a century ago.
Slide 6
6 BCG protects against severe disease in children 64% efficacy
against TBM 78% efficacy against disseminated TB disease
Slide 7
The BCG Atlas 7
Slide 8
Does BCG work in adults? 8 Little evidence to suggests that BCG
protects against PTB in adults who are the source of
transmission
Slide 9
Slide 10
10 We need a new TB vaccine strategy Safe + effective .in
infants, children, and adults .and in HIV infected people What do
we mean by protection against TB? -Primary infection?
-Pauci-bacillary childhood disease? -Disseminated TBM / miliary
disease / death? -Adult-type cavitatory pulmonary TB?
Slide 11
>50 candidate TB vaccines in pre-clinical development.
Slide 12
Since Entered Phase 1 ID93 MTBVAC Clinical Trials In South
Africa
Slide 13
14 candidate TB vaccines in clinical development [BCG] VPM-1002
MTBVAC MVA-Ag85A (MVA85A) Ad35-Ag85A, 85B, TB10.4 (Aeras-402)
Mtb32,39 in ASO1E (M72) Ag85B,TB10.4 in IC31 (H4) ESAT-6,Ag85B in
IC31 (H1) ESAT-6,Ag85B,Rv2660c in IC31 (H56) Rv2608, Rv3619,
Rv3620, Rv1813 in GLA-SE (ID93 ) Birth 6,10,14 weeks Adolescence
Adulthood PrimeBoost
Slide 14
Infant TB vaccination Prime and boost strategy 14 BCG at birth
Childhood TB Disease Exposure & Infection New vaccine Adult TB
Disease Long-lasting protection against all forms of TB disease
Pre-exposure Strategy
Slide 15
The first infant TB vaccine efficacy trial since BCG. CBS News:
Tuberculosis vaccine MVA85A fails to protect babies in new study
SABC News: Key tuberculosis vaccine fails, more waiting in the
wings Deutsche Welle: There is good news. And there is bad
news.
Slide 16
16 MVA85A did not offer additional protection against TB
disease.
Slide 17
MVA85A A402M72H1HyVac4H56 Dominant CD4 T cell subset IFN- +IL-
2+TNF+ No dominance IFN- +IL- 2+TNF+; IFN- alone IL-2+TNF+ IFN- IL-
2+TNF+; IL-2+TNF+ Th17 Co- expressed with Th1 NoneIL-17 aloneVery
few CD8 T cells NonePotent IFN- +TNF+ SomeNone Whole blood ICS
assay Hawkridge et al., 2008; Scriba et al., JID 2011; Abel et al.,
AJRCCM 2010; Day et al., AJRCCM 2013 New TB vaccines induce T cells
with distinct functional patterns Viral vectored Subunit + Th1
adjuvants
Slide 18
Verreck, et al. PlosOne 2009;4:e5264. Vordermeier, et al.
Infect. Immun. 2009;77:3364. Preclinical development Animal models
of MVA85A
Slide 19
Classical Th1 cytokine responses after vaccination do not
associate with risk of TB disease Many other T cell markers also
investigated: none differed between cases and controls Ben Kagina,
many others! *BCG given at birth. Infants followed for 2 years to
assess protection; Whole blood incubation with BCG at 10 weeks of
age for 12 hours. From 5,724 enrolled infants: TB cases (n=29) TB
cases Community controls (n=55) Household controls (n=55)
Slide 20
20 Homo sapiens and Mycobacterium tuberculosis have co-evolved
Expect variation in MTB genes encoding antigens attempt to evade
host immune system Since MTB interacts with humans through
antigen-specific CD4+ or CD8+ T-cells Expect T cell epitopes to be
the most diverse genes in the MTB genome. The spread of MTB
lineages Out-of-and-back-to- Africa
Slide 21
21 T cell epitopes are highly conserved in the MTB genome
Suggests human T cell recognition offers some evolutionary benefit
to the pathogen Human T cell response Establishment of latency
Subsequent cavitation Transmission to later generations of
susceptible hosts Could vaccine-induced immunity against highly
conserved T cell epitopes perversely increase TB transmission
long-term?
Slide 22
Newborn TB vaccination BCG replacement strategy The Holy Grail
22 New vaccine at birth Childhood TB Disease Exposure &
Infection Adult TB Disease Long-lasting protection against all
forms of TB disease Pre-exposure Strategy VPM-1002 MTBVAC
Slide 23
Interrupt of TB transmission Prevent TB among young adults
Slide 24
Adult TB vaccination Prime and boost strategy 24 BCG at
birthNew VaccineTB Disease Exposure & Infection Protection
against PTB disease Post-exposure Strategy (MTB and NTM) Mtb32,39
in ASO1E ( M72 ) Ag85B,TB10.4 in IC31 ( H4 ) ESAT-6,Ag85B in IC31 (
H1 ) ESAT-6,Ag85B,Rv2660c in IC31 ( H56 ) Rv2608, Rv3619, Rv3620,
Rv1813 in GLA-SE ( ID93 )
Slide 25
Worcester, Western Cape (SATVI) Hassan Mahomed, many others.
TST+ if >5mm. Evaluate new TB vaccines for prevention of
infection (and disease) in adolescents QFT+ adolescents have 3-fold
higher TB disease incidence than QFT- (640 per 100,000 person
years) Mahomed et al, PLOS ONE 2011 Recent QFT+ converters have
8-fold higher TB disease incidence than persistent QFT- adolescents
(1,460 per 100,000 person years) Machingaidze et al, AJRCCM 2012
>60% of adolescents are TB infected before they leave High
School
Slide 26
Trials to Test Prevention of MTB Infection in Adolescents 26
QFT - 6 monthly follow-up QFT+ Healthy, BCG-vaccinated, HIV
uninfected adolescents Endpoint QFT+ Conversion (0.35 IU/mL)
Endpoint QFT+ Conversion (0.35 IU/mL) Vaccine / Placebo QFT -
Mtb32,39 in ASO1E ( M72 ) Ag85B,TB10.4 in IC31 ( H4 ) ESAT-6,Ag85B
in IC31 ( H1 ) ESAT-6,Ag85B,Rv2660c in IC31 ( H56 ) Rv2608, Rv3619,
Rv3620, Rv1813 in GLA-SE ( ID93 )
Slide 27
Thinking Out-of-the-Box To understand mechanisms of
vaccine-induced protection and demonstrate efficacy
proof-of-concept.. Identify a target population with very high risk
of incident TB Perform small, efficient Phase II trials Green Light
vaccine candidates with an efficacy signal to expand into large
Phase III trials 27
Slide 28
28 TB TREATMENT FOLLOW-UP DIAGNOSIS CURE VACCINE / PLACEBO
RECURRENT TB SERIAL SPUTUM SAFETY RELAPSE vs REINFECTION BCG
vaccinated, HIV uninfected adults Smear and culture + pulmonary TB
Trials to Test Prevention of Recurrent TB Disease Mtb32,39 in ASO1E
( M72 ) Ag85B,TB10.4 in IC31 ( H4 ) ESAT-6,Ag85B in IC31 ( H1 )
ESAT-6,Ag85B,Rv2660c in IC31 ( H56 ) Rv2608, Rv3619, Rv3620, Rv1813
in GLA-SE ( ID93 ) Risk of recurrent TB within 12 months almost 5%
*Cape Town, South Africa *Standard-of-care treatment *Optimal
adherence *Clinical trial conditions *Culture confirmed
Slide 29
Take Home Messages Many new TB vaccine candidates in
pre-clinical development Include live recombinant and subunit
vaccines, targeted at prime and/or boost strategies Prevention of
TB in adults critical to interrupt transmission Animal models
problematic in guiding up-selection for clinical development
Proof-of-concept trials in humans may detect efficacy signal to
green light expansion to large Phase III trials 29